Literature DB >> 17243616

[Acute glaucine syndrome in the physician's practice: the clinical picture and potential danger].

V I Rovinskiĭ.   

Abstract

The author describes a clinical symptom complex which appears in some patients as a central nervous system side-effect of conventional doses of glaucine, a non-narcotic antitussive preparation, used in outpatients; the symptom complex is described by the author as acute glaucine syndrome (AGS). Clinical manifestations of AGS are the following: 1) very prominent fatigue, which occurs acutely after taking a conventional dose of glaucine and making any kind of professional activity impossible at the moment; 2) very prominent sleepiness, which occurs acutely together with fatigue and is always combined with it; 3) unusual clear but somewhat estranged perception of the environment: the patient sees and understands everything and is oriented well enough, but cannot take a clear and adequate action, 4) full recovery of the impaired functions after the drug is discontinued; 5) AGS recurrence after the drug is taken again. The hallucination-like effect of glaucine, described earlier by the author of this article, which is manifested by bright and colorful visual images, may be considered a facultative AGS component. The author stresses a potential danger of AGS development in persons who control moving mechanisms or vehicles and adduces some clinical observations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17243616

Source DB:  PubMed          Journal:  Klin Med (Mosk)        ISSN: 0023-2149


  3 in total

1.  Detection of the pharmaceutical agent glaucine as a recreational drug.

Authors:  Paul I Dargan; Jenny Button; Leonard Hawkins; John R H Archer; Hanna Ovaska; Satnam Lidder; John Ramsey; David W Holt; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2008-01-16       Impact factor: 2.953

2.  A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity.

Authors:  David M Wood; Malgorzata Puchnarewicz; Atholl Johnston; Paul I Dargan
Journal:  Eur J Clin Pharmacol       Date:  2011-10-29       Impact factor: 2.953

3.  Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]).

Authors:  Satnam Lidder; Paul Dargan; Michael Sexton; Jenny Button; John Ramsey; David Holt; David Wood
Journal:  J Med Toxicol       Date:  2008-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.